Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation.
OBJECTIVE
C-reactive protein (CRP) may directly affect the progression of atherosclerosis, and therefore, may be a target for reducing disease risk. The objective was to determine whether antioxidant supplementation reduces plasma CRP in active and passive smokers.


METHODS
Randomized, double-blind, placebo-controlled, parallel group trial with 2 months exposure to study supplements.


METHODS
Berkeley and Oakland, California.


METHODS
Healthy adult men and women, consuming <4 daily servings of fruits and vegetables, and who were actively or passively exposed to cigarette smoke. Analysis was limited to participants with detectable baseline CRP concentrations and no evidence of inflammation associated with acute illness at baseline or follow-up as reflected in CRP elevations (> or =10.0 mg/L). A total of 1393 individuals were screened, 216 randomized, 203 completed the study, and 160 were included in the analysis.


METHODS
Participants were randomized to receive a placebo or vitamin C (515 mg/day) or antioxidant mixture (per day: 515 mg vitamin C, 371 mg alpha-tocopherol, 171 mg gamma-tocopherol, 252 mg mixed tocotrienols, and 95 mg alpha-lipoic acid).


METHODS
Change in plasma CRP concentration.


RESULTS
Vitamin C supplementation yielded a 24.0% reduction (95% confidence interval, -38.9% to -5.5%, p = 0.036 compared to control) in plasma CRP, whereas the antioxidant mixture and placebo produced a nonsignificant 4.7% reduction (-23.9% to 19.3%) and 4.3% increase (-15.1% to 28.2%), respectively. Results were adjusted for baseline body mass index and CRP concentrations.


CONCLUSIONS
Plasma CRP itself may serve as a potential target for reducing the risk of atherosclerosis, and antioxidants, including vitamin C, should be investigated further to confirm their CRP-lowering and anti-inflammatory effects.
Block
Gladys
G
Division of Community Health and Human Development, School of Public Health, University of California, Berkeley, California 94720, USA. Gblock@berkeley.edu
Jensen
Christopher
C
Dietrich
Marion
M
Norkus
Edward P
EP
Hudes
Mark
M
Packer
Lester
L
D000975:Antioxidants / Q000008:administration & dosage*; D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control; D001205:Ascorbic Acid / Q000008:administration & dosage*; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012907:Smoking / Q000097:blood*; D008063:Thioctic Acid / Q000008:administration & dosage; D014028:Tobacco Smoke Pollution / Q000009:adverse effects; D024508:Tocotrienols / Q000008:administration & dosage; D014815:Vitamins / Q000008:administration & dosage*; D024502:alpha-Tocopherol / Q000008:administration & dosage; D024504:gamma-Tocopherol / Q000008:administration & dosage
D000975:Antioxidants; D010919:Placebos; D014028:Tobacco Smoke Pollution; D024508:Tocotrienols; D014815:Vitamins; D008063:Thioctic Acid; D024504:gamma-Tocopherol; D002097:C-Reactive Protein; D024502:alpha-Tocopherol; D001205:Ascorbic Acid